Implantable neuromodulation market forecast to hit $16.96 billion by 2030

The implantable neuromodulation and spinal cord stimulation devices market is projected to grow from $9.31 billion in 2025 to $16.96 billion by 2030, driven by rising chronic pain, neurological disease, and demand for minimally invasive therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The market serves patients with chronic pain and neurological disorders, where demand for targeted, implantable therapies is rising. - Faster growth in wireless, rechargeable and closed-loop devices could change how long-term pain and neurostimulation care is delivered. - The expansion matters for hospitals, neurologists and device makers investing in advanced treatment infrastructure.

What happened: - The Business Research Company released its Implantable Neuromodulation and Spinal Cord Stimulation Devices Market Report 2026 on Sept. 10, 2026. - The report says the market will grow from $9.31 billion in 2025 to $10.53 billion in 2026. - The report forecasts the market will reach $16.96 billion by 2030. - North America led the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample report and the full report are available online.

The details: - The market grew on the back of rising chronic pain, wider adoption of spinal cord stimulation therapies, expansion of neurology treatment infrastructure, greater acceptance of implantable medical devices and early advances in implantable pulse generator technology. - The report projects a 13.1% CAGR from 2025 to 2026. - It projects a 12.6% CAGR through 2030. - Growth is expected to be supported by AI-powered adaptive neuromodulation systems, minimally invasive neurological therapies, personalized neurology treatment, wireless implantable devices and closed-loop neurostimulation. - The report says key trends include greater use of closed-loop adaptive neuromodulation for real-time pain management, more rechargeable implantable pulse generators, broader use of spinal cord stimulation for chronic pain and neuropathic disorders, more wireless remotely programmable devices and rising deployment of sacral neuromodulation for bladder and bowel dysfunction. - The devices deliver controlled electrical impulses to targeted nerves or the spinal cord. - Their purpose is to modulate nerve signaling and reduce symptoms tied to neurological disorders and chronic pain. - The systems use programmable stimulation technology and implantable pulse generators to provide long-lasting neuromodulation inside the body. - The report says increasing neurological disorders are a central growth driver. - The report links that rise in part to growing diabetes rates, which can damage nerves and blood vessels and raise risks of neuropathy, stroke and cognitive decline. - The devices are used to manage conditions including Parkinson's disease, epilepsy and spinal cord injuries. - The Australian Institute of Health and Welfare reported that about 425,000 Australians were living with dementia in 2024. - The same source projects that number will rise to more than 1.1 million by 2065. - Rising healthcare expenditure is another growth driver in the report. - The report says healthcare spending supports broader access to advanced pain management technologies, expands neurological treatment infrastructure and encourages patient adoption of implantable therapies. - The Office for National Statistics said UK healthcare spending reached about $370.71 billion (£317 billion) in 2024, a 6.5% nominal increase from 2023.

Between the lines: - The forecast points to a shift from basic stimulation toward more automated and personalized systems. - The focus on wireless, rechargeable and remotely programmable devices suggests the market is moving toward fewer replacement surgeries and more flexible therapy management. - The regional split suggests North America remains the commercial center for now, but faster growth in Asia-Pacific signals broader global adoption.

What's next: - The report expects continued gains through 2030 as demand for minimally invasive neurological care rises. - Device makers are likely to keep pushing adaptive, closed-loop and wireless systems as differentiators. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - More information is available through the company's marketing contact and social channels, including LinkedIn, the company's website and social media pages.